GlassScriptPhysician profile
Erica King
NPI 1891376174
$5,801.42
in general payments reported to CMS, 2019-2025
49 companies · $2,714 in 2025
The $2,714 reported for 2025 was more than what 97% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $11.68 · 2023: $46.89 · 2024: $3,029 · 2025: $2,714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,415 · Long Term Medical Supply Or Device Loan: $1,097 · Education: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,414.99 |
| Long Term Medical Supply Or Device Loan | $1,096.70 |
| Education | $278.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,449.30 | 2024-2025 | |
| Janssen Biotech, INC. | $360.94 | 2024-2025 | Rybrevant, Darzalex, Talvey |
| Pfizer INC. | $345.45 | 2024-2025 | |
| Incyte Corporation | $303.63 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
| Takeda Pharmaceuticals U.S.A., INC. | $302.72 | 2023-2025 | Fruzaqla, Ninlaro, Iclusig |
| Lilly USA, LLC | $237.86 | 2024-2025 | Jaypirca, Verzenio |
| Astrazeneca Pharmaceuticals LP | $236.53 | 2022-2025 | Imfinzi, Tagrisso, Lynparza |
| Alexion Pharmaceuticals, INC. | $211.84 | 2024-2025 | Ultomiris, Soliris |
| Celgene Corporation | $177.20 | 2024-2025 | Reblozyl |
| Eisai INC. | $138.50 | 2024-2025 | |
| Daiichi Sankyo INC. | $134.05 | 2024-2025 | Enhertu |
| Servier Pharmaceuticals LLC | $128.09 | 2024-2025 | |
| Glaxosmithkline, LLC. | $124.99 | 2024 | Ojjaara |
| Sobi, INC | $123.85 | 2024-2025 | |
| Stemline Therapeutics INC. | $122.97 | 2024-2025 | Orserdu |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $121.57 | 2024-2025 | Hizentra |
| Sumitomo Pharma America, INC. | $103.18 | 2024-2025 | Orgovyx |
| Regeneron Healthcare Solutions, INC. | $99.17 | 2024-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $89.07 | 2024 | |
| Abbvie INC. | $71.89 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $70.11 | 2025 | Givlaari |
| Pharmacosmos Therapeutics INC. | $68.83 | 2025 | Monoferric |
| Puma Biotechnology, INC. | $63.07 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $53.79 | 2025 | Opdivo |
| Acrotech Biopharma INC. | $47.56 | 2024 | Beleodaq |
| Deciphera Pharmaceuticals INC. | $45.60 | 2025 | Qinlock, Romvimza, Tgct |
| Adc Therapeutics America, INC. | $42.83 | 2024-2025 | |
| Exelixis INC. | $41.96 | 2024 | Cabometyx |
| Recordati_rare_diseases_inc. | $36.95 | 2025 | Sylvant |
| Adaptive Biotechnologies Corporation | $36.72 | 2024 | Clonoseq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.39 | 2025 | Ofev |
| Genmab U.S., INC. | $34.92 | 2024 | Epkinly |
| Karyopharm Therapeutics INC. | $30.53 | 2024-2025 | Xpovio |
| Tersera Therapeutics LLC | $28.94 | 2024 | Quzyttir |
| Tempus Ai, INC | $27.33 | 2024 | |
| Kite Pharma, INC. | $25.48 | 2025 | Yescarta |
| Merck Sharp & Dohme LLC | $21.08 | 2025 | Reblozyl, Keytruda |
| Shield Therapeutics INC | $20.20 | 2024 | |
| Beigene USA, INC. | $20.06 | 2025 | Tevimbra |
| Emd Serono, INC. | $19.62 | 2024 | |
| Taiho Oncology, INC. | $18.76 | 2024 | |
| Genzyme Corporation | $18.27 | 2025 | |
| Pharmaessentia USA Corporation | $18.10 | 2025 | Besremi |
| Array Biopharma INC | $17.97 | 2025 | Lorbrena, Braftovi |
| Genentech USA, INC. | $15.95 | 2024 | Columvi, Lunsumio, Polivy |
| Dexcom, INC. | $15.07 | 2023 | Dexcom G6 Transmitter |
| Beone Medicines USA, INC. | $15.05 | 2025 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $14.65 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Myriad Genetic Laboratories, INC. | $13.83 | 2024 | Bracanalysis Cdx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.